| OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma XK Qi, HQ Han, HJ Zhang, M Xu, L Li, L Chen, T Xiang, QS Feng, T Kang, ... Theranostics 8 (8), 2202, 2018 | 53 | 2018 |
| TNFRSF19 Inhibits TGFβ Signaling through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis C Deng, YX Lin, XK Qi, GP He, Y Zhang, HJ Zhang, M Xu, QS Feng, ... Cancer Research 78 (13), 3469-3483, 2018 | 43 | 2018 |
| SHROOM2 inhibits tumor metastasis through RhoA–ROCK pathway-dependent and-independent mechanisms in nasopharyngeal carcinoma J Yuan, L Chen, J Xiao, XK Qi, J Zhang, X Li, Z Wang, YF Lian, T Xiang, ... Cell death & disease 10 (2), 58, 2019 | 35 | 2019 |
| Induction of chemokine (C‐C motif) ligand 5 by Epstein–Barr virus infection enhances tumor angiogenesis in nasopharyngeal carcinoma W Ma, L Feng, S Zhang, H Zhang, X Zhang, X Qi, Y Zhang, Q Feng, ... Cancer science 109 (5), 1710-1722, 2018 | 30 | 2018 |
| BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc N Li, L Yang, XK Qi, YX Lin, X Xie, GP He, QS Feng, LR Liu, X Xie, ... Cell Death & Disease 9 (7), 761, 2018 | 27 | 2018 |
| A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis N Li, L Feng, HQ Han, J Yuan, XK Qi, YF Lian, BH Kuang, YC Zhang, ... Cancer Letters 381 (1), 14-22, 2016 | 26 | 2016 |
| Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation HJ Zhang, J Tian, XK Qi, T Xiang, GP He, H Zhang, X Yu, X Zhang, ... PLoS pathogens 14 (7), e1007208, 2018 | 25 | 2018 |
| Abstract P4-01-32: BAT8008, a novel Trop-2 ADC with strong bystander effect, for the treatment of Trop-2 positive cancer X Mei, W Tang, X Zhou, X Qi, S Mai, Z Zhong, S Li, J Fan, J Gan, B Tan, ... Cancer Research 83 (5), Supplement, 2023 | 1 | 2023 |
| Abstract P30: Therapeutic activation of pre-B-cell receptor signaling in high-risk pediatric ALL: exploiting TCF3 and MYC-linked vulnerabilities IR Leo, F Post, N Struyf, X Qi, L Aswad, TTT Nguyen, M Tamai, K Akahane, ... Blood Cancer Discovery 5 (2_Supplement), P30-P30, 2024 | | 2024 |
| Antibody-drug conjugates and application thereof W Tang, X Qi, X Zhou, H Yan, S Li, J Fan, S Mai, J Yu, S Li WO Patent WO2,023,061,457, 2023 | | 2023 |
| Correction: TNFRSF19 Inhibits TGFb Signaling through Interaction with TGFb Receptor Type 1 to Promote Tumorigenesis C Deng, YX Lin, XK Qi, GP He, Y Zhang, HJ Zhang, M Xu, QS Feng, ... | | 2023 |
| Abstract P4-01-12: BAT8006, a novel FRα ADC with strong bystander effect, for the treatment of advanced solid tumor S Mai, X Mei, W Tang, X Zhou, X Qi, Z Zhong, S Li, J fan, J Gan, B Tan, ... Cancer Research 83 (5), Supplement, 2023 | | 2023 |
| Antibody-drug conjugates and uses thereof W Tang, X Zhou, X Mei, H Yan, S Li, J Fan, X Qi, J Yu, S Li WO Patent WO/2022/253,284, 2022 | | 2022 |
| Application of NOP14 gene and protein thereof as marker of sensitivity of tumor to mTOR inhibitor L Feng, YX Zeng, X Qi, J Huang, B Kuang CN Patent CN108,676,882 B, 2022 | | 2022 |
